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Objectives: To evaluate the impact of SNCA polymorphisms originally identified as risk
factors for Parkinson’s disease (PD) on the clinical presentation and progression of the
disease in a large cohort of population-based patients with incident PD.
Methods: Four hundred thirty-three patients and 417 controls from three longitudinal
cohorts were included in the study. Disease progression was recorded annually for up
to 9 years using the Unified Parkinson’s Disease Rating Scale (UPDRS) or Mini-Mental
State Examination. Genotypes for five variants within the SNCA locus (rs2870004,
rs356182, rs5019538, rs356219, and rs763443) were determined. We studied the
association between each variant and disease progression using linear mixed-effects
regression models.
Results: The clinical profile of the patients with PD at the point of diagnosis was
highly uniform between genotype groups. The rs356219-GG genotype was associated
with a higher UPDRS II score than A-allele carriers (β = 1.52; 95% confidence interval
0.10–2.95; p = 0.036), but no differences were observed in the rate of progression of
the UPDRS II scores. rs356219-GG was also associated with a faster annual change
in Mini-Mental State Examination score compared with A-carriers (β = 0.03; 95%
confidence interval 0.00–0.06; p = 0.043).
Conclusions: We show that the known PD-risk variant rs356219 has a minor effect on
modifying disease progression, whereas no differences were associated with rs2870004,
rs356182, rs5019538, and rs763443. These findings suggest that SNCA variants
associated with PD risk may not be major driving factors to the clinical heterogeneity
observed for PD.
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INTRODUCTION
Parkinson’s disease (PD) is a neurodegenerative disorder
characterized by the core motor symptoms, bradykinesia,
resting tremor, rigidity, and postural instability, though often
accompanied by a wide spectrum of additional motor and
non-motor signs (1). The severity and rate of progression of
clinical symptoms in PD are highly variable between patients.
Some patients experience mild motor decline and non-motor
symptoms, whereas some experience fast deterioration in
motor symptoms and prominent non-motor symptoms. These
differences are in part predicted by sex, age at diagnosis,
motor phenotype, and disease severity (2). Similarly, the timing
and rate of cognitive decline vary widely among individuals
with PD (3), and certain measures, including older age or
differences in motor phenotype at diagnosis, predict a more
rapid rate of cognitive decline in subgroups of patients (4).
The observed heterogeneity can pose prognostic difficulties in a
clinical setting, compromising both the planning of appropriate
patient management and clinical trial design.
Although heterogeneity in PD is widely recognized, the
biological factors modulating the progression remain largely
unknown. Association studies have shown that common genetic
variance contributes to the risk of developing idiopathic PD (5,
6), and some of these same variants may modify the progression
of clinical symptoms (7, 8). The SNCA gene encodes α-synuclein,
the main protein component of Lewy bodies, which are the
pathological hallmark of sporadic PD (9), and genetic variants in
the SNCA region repeatedly have the strongest association with
PD risk in genome-wide association studies (GWASs) (5, 10–12).
To date, data on the impact of these SNCA polymorphisms on PD
progression are scarce, and further investigation in longitudinal
studies of patients with PD is needed to refine the link between
the genetic variance in SNCA and disease course.
Here, we explored the effects of five SNCA single nucleotide
polymorphisms (SNPs), rs2870004, rs356182, rs5019538,
rs356219, and rs763443, on the presentation of PD at the time
of diagnosis and the progression of the motor, functional, and
cognitive impairment over up to 9 years of regular follow-up,




Three longitudinal cohorts were included in the study: the
Norwegian ParkWest study (13), the Parkinsonism Incidence
in North-East Scotland (PINE) study (14), and the Swedish
New Parkinson Patient in Umeå (NYPUM) study (15). These
cohorts provide on-going prospective follow-up of population-
based incidence studies of all newly diagnosed PD patients
identified in specific geographic regions, initiated between 2002
and 2009. Diagnosis of PD was made according to UK Brain
Bank criteria by a neurologist specialized in movement disorders
at the baseline visit with continued reassessment at follow-up
visits. Participant recruitment and follow-up are summarized in
Supplementary Figure 1. Briefly, 605 patients were enrolled: 212
in ParkWest, 211 in PINE, and 182 in NYPUM. Of these, 70
have had a diagnosis other than PD during follow-up, 7 did not
consent to follow-up, 57 did not consent to genotyping, and 38
have no DNA sample available, or DNA could not be genotyped.
Five hundred twenty-three control subjects were recruited from
the same areas: 201 in ParkWest, 266 in PINE, and 56 in the
NYPUM study. Of these, 70 have no DNA sample available, or
DNA could not be genotyped, 30 did not consent to genotyping,
and 6 were diagnosed with PD during follow-up. The remaining
433 PD patients and 417 controls consented to regular follow-up
and were eligible for this study. At the time of the study, data
from clinical visits for a period of up to 9 years were available
(Supplementary Figure 1).
Respective ethical committees approved studies: The Western
Norway Regional Committee for Medical and Health Research
Ethics, the Multi-Centre Research Ethics Committee for
Scotland, and the Regional Ethics Review Board in Umeå. All
participants signed written informed consent.
Clinical Assessment
The clinical assessments have been described in detail, and the
same procedures were followed for each cohort (13–15). At
baseline, general medical and neurological examinations and
semi-structured interviews were performed for all participants to
establish medical, drug, and family history (first-degree relative
with PD, self-reported). No cases of familial PD were recorded.
Patients with PD were assessed at baseline and annual follow-up
visits using Hoehn and Yahr staging (16), the Unified Parkinson’s
Disease Rating Scale (UPDRS) II (activities of daily living) and
part III (motor examination) (17), and the Mini-Mental State
Examination (MMSE) (18) (in ParkWest, MMSE was evaluated
at baseline, the first annual visit and every second year after that),
and controls were assessed at baseline and follow-up visits using
theMMSE. Home visits were offered to those unable or unwilling
to come to the clinic to minimize attrition bias.
Based on subscores of UPDRS III (motor examination), we
derived measures of tremor (sum of items 20 and 21), rigidity
(sum of item 22), bradykinesia (sum of items 23, 24, 25, 26, and
31), and axial impairment (sum of items 27, 28, 29, and 30). We
calculated levodopa-equivalent doses (LEDs) in accordance with
published recommendations (19).
Genotyping of SNCA Variants
We selected five SNCA polymorphisms (rs2870004, rs356182,
rs5019538, rs356219, and rs763443) identified as contributing
to a person’s risk of developing PD in the largest genome-wide
association studies (5, 20) and the largest dedicated genetic study
of SNCA (6) to date.
Genomic DNA was extracted from peripheral blood using
standard methods. Allelic discrimination analysis was performed
using predesigned TaqMan SNP genotyping assay (Thermo
Fisher Scientific) for rs2870004 (Assay ID: C__26455957_20),
rs356182 (C___3208989_10), rs356219 (C___1020193_10), and
rs763443 (C___1902284_10) and a custom assay for rs5019538
(Thermo Fisher Scientific). The amplification reactions were
performed using the ABI PRISM 7300 Real-Time PCR System
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(Applied Biosystems) with SDS v1.4 software. The call rates were
>99% for each SNP, and the concordance rate was 98%.
Statistical Methods
All between-group comparisons were performed using IBM SPSS
Statistics version 26.0 (Armonk, NY). The regression analysis
was done in R version 4.0.2. No differences were observed
between the unadjusted and adjusted analyses unless otherwise
stated. Two-tailed p-values < 0.05 were considered significant,
and correction for multiple testing was not performed in this
exploratory analysis. As there is insufficient evidence regarding
the best genetic model to analyze the effect of SNCA SNPs
on disease progression, we took an exploratory approach and
included both the recessive and dominant genetic models in the
analysis plan.
Baseline Analysis
Continuous data were summarized using descriptive statistics,
whereas categorical data were reported as counts and
percentages. Between-group differences in demographic
variables were assessed for significance using the Mann–
Whitney U tests and χ2 tests, as appropriate. Logistic regression
(categorical outcome) or linear regression (continuous outcome)
was used to test the association between SNCA genotypes
and PD risk or clinical outcomes at baseline, without and
with adjustment for age at baseline and sex. The results of
multivariable analyses were presented as odds ratios (ORs) with
95% confidence intervals (CIs) and p-values.
Longitudinal Analysis
We investigated the association between each of the SNCA
genotypes and disease progression using three different linear
mixed models. The outcome variables for the three models were
repeated measurements of UPDRS part II, UPDRS part III, or
MMSE total score. MMSE total scores were transformed using
log (30 – MMSE + 1) to achieve normality. Time in the study
(as a continuous variable) and the SNCA genotype (as a binary
categorical variable) were included as fixed effects. Patient IDs
were included as random intercepts. The interaction between
time and the genotype was included as a fixed effect to assess how
the SNCA genotype influenced disease progression. The analyses
were performed without adjustment and with adjustment for
the following variables as fixed effects: study cohort, sex, age
at baseline, and duration of motor symptoms at baseline. For
MMSE, years of education were also included as a fixed effect.
For UPDRS II and III, the effect sizes were similar after additional
adjustment for LED at each visit (data not shown). Each model
had a first-order autoregressive covariance structure. The plot of
predictive margins was created using the command margins in
Stata 16.00.
RESULTS
Baseline Characterization of Study
Population
Of the total 850 participants eligible for the study, 433 were
patients with PD, and 417 were control subjects (Table 1). The
mean age at baseline for PD patients was 69.9 ± 9.6 years, with
TABLE 1 | Baseline demographic and clinical characteristics of patients and
controls included in study.
Variablea NC PD p value
Total, N 417 433
Male, N (%) 242 (58.0) 263 (60.7) 0.42
Age at baseline, years 69.6 (±10.2) 69.9 (±9.6) 0.68
Age at first motor symptoms, years 67.9 (±9.6)
Positive family history, N (%) 25 (6.9) 56 (13.0) 0.005
Education, years 12.5 (±3.0) 11.2 (±3.6) <0.001
UPDRS II 9.2 (±4.8)
UPDRS III 24.7 (±11.4)
Hoehn and Yahr 2.1 (±0.7)
MMSE, median (IQR) 29.0 (2.0) 29.0 (3.0) <0.001
NC, normal control; PD, Parkinson’s disease; N, count; UPDRS, Unified Parkinson’s
Disease Rating Scale; MMSE, Mini-Mental State Examination, IQR, interquartile range.
Values presented as mean (± standard deviation) unless stated otherwise.
Significant p-values (p < 0.05) indicated in bold. P-values calculated using χ2 test,
Mann–Whitney U-test, as appropriate.
aMissing data for family history, 1 PD and 56 NC; education, 20 NC; UPDRS II, 4 PD;
MMSE, 76 PD and 7 NC.
the proportion of males 60.7%. At the baseline examination, the
patients and controls differed with regard to the level of family
history of PD (p < 0.001), the years of education (p= 0.005), and
theMMSE score (p< 0.001) but not the distribution of sex or age.
SNCA Variants and Risk of Parkinson’s
Disease
The distributions of the five SNCA SNP genotypes and the minor
allele frequencies in PD patients and controls are summarized
in Supplementary Table 1. No deviations fromHardy–Weinberg
equilibrium were observed for the allele frequencies in patients
and controls. Logistic regression analysis was performed to
determine if genotype status was associated with a higher
incidence of PD, using either the recessive or dominant model
(Table 2). In unadjusted analysis, rs356182-G allele carrier status
was significantly associated with increased risk of PD compared
with noncarriers (OR= 1.33; 95% CI 1.01–1.75; p= 0.046). This
remained significant after adjustment for age at baseline and sex
(OR = 1.32; 95% CI 1.00–1.75; p = 0.049). No other significant
associations were identified between genotype status and risk
of PD.
SNCA Variants and Baseline Parkinson’s
Disease Profile
Analysis of the association of SNCA genotypes and the
demographic characteristics of the patients with PD showed no
significant differences between groups, except for a higher mean
number of years of education for the carriers of rs2870004-TT
genotype as compared with rs2870004 A-allele carriers (13.2 ±
4.4 vs. 11.1 ± 3.5 years; p = 0.021, Supplementary Table 2).
At the time of PD diagnosis, the rs356219-GG genotype
was associated with higher UPDRS II scores (p = 0.017)
(Supplementary Table 2). No differences were shown between
baseline clinical presentation of PD and SNCA genotypes for the
other SNPs investigated (Supplementary Tables 2, 3).
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TABLE 2 | Comparison of genotypes of each SNCA variant between PD patients
and controls.
SNP Genotype PD, N (%) NC, N (%) OR (95% CI) p-value
rs2870004
Recessive AA + AT 411 (95.1) 397 (95.7) 1.00
TT 21 (4.9) 18 (4.3) 1.13 (0.59–2.15) 0.71
Dominant AA 275 (63.7) 258 (62.2) 1.00
AT + TT 157 (36.3) 157 (37.8) 0.94 (0.71–1.24) 0.66
rs356182
Recessive AA + AG 363 (83.8) 361 (87.2) 1.00
GG 70 (16.2) 53 (12.8) 1.31 (0.89–1.93) 0.17
Dominant AA 151 (34.9) 172 (41.5) 1.00
AG + GG 282 (65.1) 242 (58.5) 1.32 (1.00–1.75) 0.049
rs5019538
Recessive AA + AG 382 (88.4) 371 (89.4) 1.00
GG 50 (11.6) 44 (10.6) 1.14 (0.72–1.70) 0.64
Dominant AA 193 (44.7) 199 (48.0) 1.00
AG + GG 239 (55.3) 216 (52.0) 1.14 (0.87–1.50) 0.34
rs356219
Recessive AA + AG 354 (81.8) 355 (85.3) 1.00
GG 79 (18.2) 61 (14.7) 1.30 (0.90–1.87) 0.16
Dominant AA 141 (32.6) 155 (37.3) 1.00
AG + GG 292 (67.4) 261 (62.7) 1.23 (0.92–1.63) 0.16
rs763443
Recessive CC + CT 331 (76.6) 317 (76.2) 1.00
TT 101 (23.4) 99 (23.8) 0.98 (0.71–1.34) 0.89
Dominant CC 122 (28.2) 105 (25.2) 1.00
CT + TT 310 (71.8) 311 (74.8) 0.86 (0.63–1.16) 0.32
SNP, single nucleotide polymorphism; PD, Parkinson’s disease; N, count; NC, normal
control; OR, odds ratio; CI, confidence intervals.
Significant p-values indicated in bold. P-values calculated using logistic regression
with adjustment.
Effect of SNCA Genotypes on Motor and
Functional Impairment
Linear mixed-effects regression analysis with adjustment for age,
sex, study cohort, and duration of motor symptoms at baseline
revealed that there were no significant differences between any
of the SNCA genotypes and the rate of annual changes in
UPDRS II or III scores measured for up to 9 years (Table 3;
Supplementary Table 4). Further adjustment for time-varying
LED did not change the significance of the results (data not
shown). However, the linear mixed-effects regression analysis
reproduced the association between the rs356219 genotype and
UPDRS II scores at baseline, with the carriers of rs356219-GG
genotype having a 1.52-point higher UPDRS II score during all
9 years of the study in comparison with the carriers of A-allele
in adjusted analysis (β = 1.52; 95% CI 0.10–2.95; p = 0.036)
(Table 3, Figure 1A).
rs356219 Is Associated With Faster
Cognitive Decline
The rs356219 genotype was associated with a difference in the
rate of annual change in MMSE score (Table 3, Figure 1B), with
carriers of rs356219-GG predicted to experience a faster decrease
in MMSE scores over the 9 years of follow-up compared with an
A-allele carrier (β = 0.03; 95% CI 0.00–0.06; p = 0.043) after
the adjustment for study cohort, sex, age at baseline, duration
of motor symptoms at baseline, and years of education. For
MMSE, the estimated coefficients cannot be directly interpreted
in terms of the annual change in performance, as the data were
transformed before analysis. The adjusted model predicts that
SNCA rs356219-GG carriers would experience on average a fall
from 28.9 to 25.1 (95% CI 23.9–26.1) points during 9 years,
whereas the MMSE score of A-allele carriers would fall from
29.0 to 26.6 (95% CI 26.2–27.0; p = 0.043). Analysis of the
association of rs356219 with the rate of change in MMSE score
in the control group showed no association between rs356219-
GG status and the annual change in MMSE (data not shown).
We did not observe any significant effects of the other SNCA
genotypes on cognitive impairment measured using MMSE
(Table 3; Supplementary Table 4).
DISCUSSION
In this study, we explored the effect of five SNCA polymorphisms
linked to PD risk on the progression of the disease. Based on
the prospective assessment of three population-based incident
cohorts of patients with PD, we show an association between
rs356219 and the rate of cognitive decline measured from the
time of PD diagnosis. The predicted size of the effect of rs356219
on the annual change in cognitive impairment was small, and
further, the four other PD risk SNPs investigated had no effect
on longitudinal measures of disease severity. Together, these data
suggest that although common variants in SNCA are important
risk factors for PD, these SNPs play a minor role in modifying the
progression of PD.
Patients with the rs356219-GG genotype experienced a faster
rate of cognitive decline measured by MMSE than A-allele
carriers over the 9 years of follow-up. No differences between
genotype groups and the annual change in MMSE score were
observed for the control subjects over the same follow-up period,
indicating that this effect is disease-specific. Similar to our
findings, Luo et al. (21) found an association between the rate
of cognitive impairment and rs356219. However, in their study
of patients with PD from China, carriers of the G-allele had a
decreased risk of cognitive decline, indicating that the G allele
might have a protective role in this population (21). In an
analysis of European patients with PD, Goris et al. reported
no association of rs356219 with the annual change in MMSE
(22). Notably, this study only followed participants for the first
3.5 years from diagnosis, and based on the predictions from
our population, a longer follow-up period would be required to
observe the effects of rs356219 on changes in MMSE. In keeping
with our findings at the time of PD diagnosis, no difference
was observed between rs356219 and mild cognitive impairment
in newly diagnosed patients (23). Further, in patients in the
later stages of PD (average disease duration at examination 8.8
years), carriers of the rs356219-G allele were at higher risk of
cognitive impairment (24). However, a large study analyzing a
broad battery of cognitive tests found no association with this
SNP in PD patients with amean of 6.6 years disease duration (25).
Our models predicted that patients with the rs356219-GG
genotype would experience on average a one and a half-point
larger decrease in MMSE score compared with rs356219-A
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TABLE 3 | Association between annual change in clinical assessments of PD and SNCA polymorphisms assuming a recessive model.
rs2870004a rs356182a rs5019538a rs356219a rs763443a
AA + AT vs. TT AA + AG vs. GG AA + AG vs. GG AA + AG vs. GG CC + CT vs. TT
β (95% CI) p β (95% CI) p β (95% CI) p β (95% CI) p β (95% CI) p
UPDRS IIb
Main effect −0.32 (−2.87; 2.23) 0.81 1.02 (−0.48; 2.52) 0.18 0.82 (−0.91; 2.54) 0.35 1.52 (0.10; 2.95) 0.036 −0.50 (−1.80; 0.79) 0.44
Interaction with time 0.13 (−0.30; 0.55) 0.56 0.09 (−0.18; 0.36) 0.52 −0.08 (−0.38; 0.23) 0.63 0.04 (−0.22; 0.29) 0.79 −0.01 (−0.24; 0.21) 0.92
UPDRS IIIb
Main effect 0.27 (−4.82; 5.36) 0.92 0.86 (−2.13; 3.86) 0.57 −0.47 (−3.91; 2.97) 0.79 1.51 (−1.34; 4.36) 0.30 −0.11 (−2.70; 2.47) 0.93
Interaction with time −0.24 (−1.03; 0.54) 0.55 0.17 (−0.33; 0.66) 0.51 −0.14 (−0.70; 0.41) 0.61 0.08 (−0.39; 0.55) 0.74 −0.29 (−0.70; 0.12) 0.17
MMSEc
Main effect 0.03 (−0.29; 0.35) 0.86 0.06 (−0.12; 0.25) 0.50 0.01 (−0.21; 0.22) 0.95 0.03 (−0.14; 0.21) 0.70 −0.12 (−0.27; 0.04) 0.15
Interaction with time −0.01 (−0.05; 0.04) 0.80 0.02 (−0.01; 0.05) 0.13 0.00 (−0.03; 0.03) 0.90 0.03 (0.00; 0.06) 0.043 0.00 (−0.03; 0.02) 0.94
UPDRS, Unified Parkinson’s Disease Rating Scale; MMSE, Mini-Mental State Examination; CI, confidence intervals.
Significant p-values (p < 0.05) indicated in bold. Main effect indicates effect of carrier status on intercept, and interaction with time indicates effect of carrier status on slope (change in
value per year) of model.
aGenotypes grouped according to a recessive genetic model and association with change in clinical assessments assessed using linear mixed models. Reference group is given first.
bAdjusted for study cohort, sex, age at baseline, duration of motor symptoms at baseline.
cAdjusted for study cohort, sex, age at baseline, duration of motor symptoms at baseline, and years of education at baseline. MMSE score transformed before analysis.
FIGURE 1 | Prediction of UPDRS II and MMSE scores over time. Average predicted UPDRS II (A) and MMSE (B) scores with confidence bands for first 9 years after
diagnosis of PD for rs356219-GG allele carriers (orange, circles) and rs356219-A allele carriers (blue, triangles). UPDRS, Unified Parkinson’s Disease Rating Scale;
MMSE, Mini-Mental State Examination.
carriers after 9 years. This small difference suggests that the
rs356219 genotype alone is not a strong predictor of cognitive
decline in individuals with PD; however, subtle changes of
cognitive function may prove to be clinically meaningful in
combination with other risk factors. Recently, the rs356219
SNCA variant has been suggested to interact in a synergic manner
with GBA variants to alter the disease course. In a longitudinal
study of newly diagnosed patients with PD, rs356219-GG was
associated with faster progression to Hoehn and Yahr stage 3 in
GBA-associated PD but had no detectable effect in noncarriers of
a GBA variant (26). This indicates that a synergistic interaction
between different genetic risk variants could amplify their effect
on disease outcomes.
In this study, we did not observe any significant associations
between each of the five SNCA SNPs and the development of
motor or functional impairment. Few studies have analyzed the
effect of SNCA SNPs on the annual change in UPDRS scores
(27, 28), and previously, only the rs356182-GG genotype has
been linked to the rate of motor progression, with GG carriers
exhibiting a slower rate of change in UPDRS III scores (28).
A notable difference to our study is that the patients were not
followed from the time of diagnosis but were first examined
after a median disease duration of 7 years, and it is possible that
the effect of this SNP on modifying motor impairment is more
prominent in the later stages of PD. This highlights one of the
many difficulties in modeling the relationship between measures
of motor impairment and genetic variants, as, in addition to
disease duration, the results can also be impacted by differences
in the number and frequency of study visits and the length of
follow-up. In our study, subjects were followed annually from the
time of diagnosis. Although our findings support that common
SNCA SNPs do not contribute to variability in the rate of motor
impairment, it will be important to follow up these findings in the
later phases of the disease.
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Each of the SNCA variants included in our study has been
previously linked to the risk of PD (5, 6). In our study population,
we observed an association between rs356182 and disease risk
under the dominant model. This variant appeared as the top
hit with the strongest association with PD risk in consecutive
GWASs (5, 10, 11). Two of the SNPs included in our study,
rs2870004 and rs5019538, were only recently identified as risk
variants for PD in the largest GWASs performed to date (5) or
a comprehensive SNCA locus study (6) and have not previously
been studied in the context of PD phenotype. In this study, we
present the first assessment of the disease-modifying effect of
these SNPs and find that they do not have a major impact on
the presentation or progression of PD. This is in keeping with
recent work showing that a genetic risk score based on 31 SNPs
associated with the risk of PD was not associated with changes in
clinical progression (8).
The present study has notable strengths. All cohorts included
in our work are population-based and recruited incident cases
representative of the general PD population, as opposed to
general research studies, which are generally unrepresentative of
the population age distribution of PD (29). Every center used
the same standardized diagnostic criteria for PD and clinical
outcomes, and patients were all recruited early in the disease and
followed prospectively with more than 3,000 study visits. The
rate of attrition for reasons other than death was very low, and
potential selection bias was minimized by introducing remote
visits for those unable to attend clinic visits. The study also has
limitations. Firstly, we were only able to include 433 patients with
PD and 417 controls, limiting the power of the study to detect
small effects, although notably, our study is the largest to date
to study the effects of these SNCA polymorphisms on disease
progression. Furthermore, we acknowledge that our exploratory
approach, including five SNCA SNPs and two genetic models,
increases the risk of false positives. Therefore, the significance of
our findings should be interpreted with caution, and this work
should be validated. Further, we did not address the potential
confounding effect of death on the association with disease
outcomes in carriers of these SNCA SNPs.
In summary, we report the comprehensive analysis of five
SNCA PD risk SNPs and their association with long-term
disease progression in the largest study to date of patients with
PD followed from diagnosis. We find that rs356219 is linked
with subtle differences in PD clinical measures, whereas no
differences are associated with rs2870004, rs356182, rs5019538,
and rs763443, suggesting that these genetic variants do not play a
large role in modifying disease progression. This illustrates that
PD is a complex disease in which the mechanisms underlying
the association of the SNCA GWAS signals with PD risk may
not be driving factors to the large clinical heterogeneity observed
throughout the disease.
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